BlueLinx (BXC) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BlueLinx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BXC shares.
View BXC analyst ratings or view top-rated stocks.

1 brokers have issued 1-year price targets for BlueLinx's stock. Their BXC share price forecasts range from $105.00 to $105.00. On average, they expect the company's stock price to reach $105.00 in the next twelve months. This suggests a possible upside of 28.5% from the stock's current price.
View analysts price targets for BXC or view top-rated stocks among Wall Street analysts.

BlueLinx's stock was trading at $71.11 at the beginning of the year. Since then, BXC stock has increased by 14.9% and is now trading at $81.73.
View the best growth stocks for 2023 here.

BlueLinx saw a increase in short interest in August. As of August 31st, there was short interest totaling 392,700 shares, an increase of 8.9% from the August 15th total of 360,600 shares. Based on an average daily trading volume, of 77,800 shares, the days-to-cover ratio is currently 5.0 days. Currently, 4.5% of the shares of the stock are short sold.
View BlueLinx's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our BXC earnings forecast.

BlueLinx Holdings Inc. (NYSE:BXC) announced its earnings results on Tuesday, August, 1st. The construction company reported $2.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.96 by $0.21. The construction company had revenue of $815.97 million for the quarter, compared to analyst estimates of $893.80 million. BlueLinx had a net margin of 3.80% and a trailing twelve-month return on equity of 23.13%.

ETFs with the largest weight of BlueLinx (NYSE:BXC) stock in their portfolio include First Trust Active Factor Small Cap ETF (AFSM).Invesco Russell 2000 Dynamic Multifactor ETF (OMFS).

56 employees have rated BlueLinx Chief Executive Officer Mitch Lewis on Glassdoor.com. Mitch Lewis has an approval rating of 49% among the company's employees. This puts Mitch Lewis in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other BlueLinx investors own include Novavax (NVAX), Micron Technology (MU), Co-Diagnostics (CODX), Livongo Health (LVGO), Intel (INTC), Maxar Technologies (MAXR), Civeo (CVEO), Nautilus (NLS), Sorrento Therapeutics (SRNE) and Hologic (HOLX).

BlueLinx trades on the New York Stock Exchange (NYSE) under the ticker symbol "BXC."

BlueLinx's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.39%), Voss Capital LLC (8.14%), Dimensional Fund Advisors LP (5.60%), Gendell Jeffrey L (5.35%), State Street Corp (2.02%) and Geode Capital Management LLC (1.94%). Insiders that own company stock include Carol B Yancey, Kim S Fennebresque, Mitchell B Lewis, Mitchell B Lewis, Nokomis Capital, LLC and Shyam K Reddy.
View institutional ownership trends.

Shares of BXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BXC stock can currently be purchased for approximately $81.73.

BlueLinx (NYSE:BXC) has a market capitalization of $735.82 million and generates $3.52 billion in revenue each year. The construction company earns $296.18 million in net income (profit) each year or $14.52 on an earnings per share basis.

The company employs 2,100 workers across the globe.

BlueLinx's mailing address is 1950 SPECTRUM CIRCLE SUITE 300, MARIETTA GA, 30067. The official website for the company is www.bluelinxco.com. The construction company can be reached via phone at (770) 953-7000, via email at ir@audentestx.com, or via fax at 770-221-8902.